1.4(top 50%)
impact factor
407(top 50%)
papers
7.4K(top 20%)
citations
42(top 20%)
h-index
1.7(top 50%)
impact factor
840
all documents
7.6K
doc citations
60(top 20%)
g-index

Top Articles

#TitleJournalYearCitations
1Clinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal DoxorubicinClinical Lymphoma and Myeloma2008171
2Phase II Evaluation of Gemcitabine Monotherapy for Cutaneous T-Cell LymphomaClinical Lymphoma and Myeloma2006137
3Treatment of Multiple Myeloma: A Comprehensive ReviewClinical Lymphoma and Myeloma2009135
4Hodgkin Lymphoma: An Update on its Biology with New Insights into ClassificationClinical Lymphoma and Myeloma2009127
5Update on Recommendations for Assessing Response from the Third International Workshop on Waldenström's MacroglobulinemiaClinical Lymphoma and Myeloma2006107
6Infectious Complications in Patients With Chronic Lymphocytic Leukemia: Pathogenesis, Spectrum of Infection, and Approaches to ProphylaxisClinical Lymphoma and Myeloma2009106
7Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive FactorsClinical Lymphoma and Myeloma2009101
8New Thrombopoietic Growth FactorsClinical Lymphoma and Myeloma200995
9Promoter Hypermethylation of the MEG3 (DLK1/MEG3) Imprinted Gene in Multiple MyelomaClinical Lymphoma and Myeloma200888
10Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell LymphomaClinical Lymphoma and Myeloma200988
11Waldenström's Macroglobulinemia: Hyperviscosity Syndrome and CryoglobulinemiaClinical Lymphoma and Myeloma200986
12Updated Guidelines on the Management of Cytomegalovirus Reactivation in Patients with Chronic Lymphocytic Leukemia Treated with AlemtuzumabClinical Lymphoma and Myeloma200682
13Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Receiving Stem Cell Transplantation for Multiple MyelomaClinical Lymphoma and Myeloma200679
14Cardiac Involvement with Lymphoma: A Review of the LiteratureClinical Lymphoma and Myeloma200878
15Rituximab Combined With MACOP-B or VACOP-B and Radiation Therapy in Primary Mediastinal Large B-Cell Lymphoma: A Retrospective StudyClinical Lymphoma and Myeloma200970
16T-Cell Lymphoblastic Lymphoma and T-Cell Acute Lymphoblastic Leukemia: A Separate Entity?Clinical Lymphoma and Myeloma200965
17Therapeutic Targeting of NOTCH1 Signaling in T-Cell Acute Lymphoblastic LeukemiaClinical Lymphoma and Myeloma200964
18Comparative Outcomes Following CP-R, CVP-R, and CHOP-R in Waldenström's MacroglobulinemiaClinical Lymphoma and Myeloma200963
19Value of [18F]Fluorodeoxyglucose Positron Emission Tomography in the Management of Follicular Lymphoma: The End of a Dilemma?Clinical Lymphoma and Myeloma200860
20Bortezomib and the Increased Incidence of Herpes Zoster in Patients with Multiple MyelomaClinical Lymphoma and Myeloma200859
21Rituximab plus Short-Duration Chemotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan as First-Line Treatment for Patients with Follicular Non-Hodgkin Lymphoma: A Phase II Trial of the Sarah Cannon Oncology Research ConsortiumClinical Lymphoma and Myeloma200956
22Amyloidosis: Diagnosis and ManagementClinical Lymphoma and Myeloma200554
23Non-Hodgkin's Lymphoma Involving the Liver: Clinical and Therapeutic ConsiderationClinical Lymphoma and Myeloma200654
24AMD3100 Affects Autograft Lymphocyte Collection and Progression-Free Survival After Autologous Stem Cell Transplantion in Non-Hodgkin LymphomaClinical Lymphoma and Myeloma200754
25Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function ImpairmentClinical Lymphoma and Myeloma200854
26Late Non-Neoplastic Events in Patients with Aggressive Non-Hodgkin's Lymphoma in Four Randomized European Organisation for Research and Treatment of Cancer TrialsClinical Lymphoma and Myeloma200550
27Targeting B-Lymphocyte Stimulator/B-Cell Activating Factor and a Proliferation-Inducing Ligand in Hematologic MalignanciesClinical Lymphoma and Myeloma200650
28Arsenic Compounds in the Treatment of Multiple Myeloma: A New Role for a Historical RemedyClinical Lymphoma and Myeloma200650
29IgM Monoclonal Gammopathy of Undetermined Significance and Smoldering Waldenström's MacroglobulinemiaClinical Lymphoma and Myeloma200950
30High-Risk Childhood Acute Lymphoblastic LeukemiaClinical Lymphoma and Myeloma200950
31Update of the M. D. Anderson Cancer Center Experience with Hyper-CVAD and Rituximab for the Treatment of Mantle Cell and Burkitt-Type LymphomasClinical Lymphoma and Myeloma200749
32Incidence of Lymphoma in Patients with Rheumatoid Arthritis: A Systematic Review of the LiteratureClinical Lymphoma and Myeloma200849
33Assessment of Bone Marrow Response in Waldenström's MacroglobulinemiaClinical Lymphoma and Myeloma200948
34A Comparison of Inpatient Length of Stay and Costs Among Patients with Hematologic Malignancies (Excluding Hodgkin Disease) Associated with and Without Acute Renal FailureClinical Lymphoma and Myeloma200847
35Multiple Myeloma and Hyperammonemic Encephalopathy: Review of 27 CasesClinical Lymphoma and Myeloma200847
36Prognostic Relevance of 6q Deletion in Waldenström's Macroglobulinemia: A Multicenter StudyClinical Lymphoma and Myeloma200947
37Response to Bortezomib and Activation of Osteoblasts in Multiple MyelomaClinical Lymphoma and Myeloma200646
38Bortezomib-Induced Tumor Lysis Syndrome in Multiple MyelomaClinical Lymphoma and Myeloma200646
39AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical EntityClinical Lymphoma and Myeloma200945
40Predictive Role of Positron Emission Tomography in the Outcome of Patients with Follicular LymphomaClinical Lymphoma and Myeloma200744
41An Observational, Retrospective Analysis of Retreatment with Bortezomib for Multiple MyelomaClinical Lymphoma and Myeloma200844
42Monoclonal Gammopathy of Undetermined SignificanceClinical Lymphoma and Myeloma200543
43Pentostatin/Cyclophosphamide with or Without Rituximab: An Effective Regimen for Patients with Waldenström's Macroglobulinemia/Lymphoplasmacytic LymphomaClinical Lymphoma and Myeloma200543
44Fatal Interstitial Pneumonitis Related to Rituximab-Containing RegimenClinical Lymphoma and Myeloma200643
45Cold Agglutinin–Mediated Autoimmune Hemolytic Anemia in Waldenström's MacroglobulinemiaClinical Lymphoma and Myeloma200943
46Phase I Trial of First-Line Bortezomib/Thalidomide plus Chemotherapy for Induction and Stem Cell Mobilization in Patients with Multiple MyelomaClinical Lymphoma and Myeloma200642
47Bing-Neel Syndrome RevisitedClinical Lymphoma and Myeloma200942
48Successful Completion of Pregnancy in a Patient With Chronic Myeloid Leukemia Without Active Intervention: A Case Report and Review of the LiteratureClinical Lymphoma and Myeloma200942
49Minimal Residual Disease Quantitation in Acute Myeloid LeukemiaClinical Lymphoma and Myeloma200942
50CD52 Is Expressed on Human Mast Cells and Is a Potential Therapeutic Target in Waldenström's Macroglobulinemia and Mast Cell DisordersClinical Lymphoma and Myeloma200641